|
 Welcome to D-Gen Ltd
D-Gen is a
research-based bio-medical Company which innovates in the field of
prion-related disease by identifying, developing and exploiting
proprietary diagnostic and therapeutic targets and technologies.
D-Gen is committed to utilising the latest research in developing
products and services that meet the global animal and public health
challenge posed by prion diseases.
D-Gen was formed in May 2000 as a University spin-out company to
commercialise relevant research emanating from the work of Professor John
Collinge's team at the Medical Research Council (MRC) Prion Unit (now based at
the Institute of Neurology, University College London). The MRC Prion Unit was
set up to create an international centre of excellence. It plays a key role in
linking basic science to clinical research and has contributed to some of the
most significant advances in the field of prion diseases. These include:
-
producing the first experimental
evidence of a link between BSE and CJD
-
replicating the conversion of
normal prion protein into the abnormal, disease associated type in the
laboratory using a genetically engineered form of the prion protein
-
developing a novel test to
detect abnormal prion protein in human tonsils and to diagnose vCJD in vivo
-
developing methods for prion
decontamination of surgical instruments
-
showing that monoclonal
antibodies could form the basis of future medicine to treat CJD.
D-Gen's shareholders include
Imperial College London, The Medical Research Council (MRC), The Wellcome Trust
Ltd, University of Bristol and a number of inventor scientists.
Find out how we
can help you...
Our Technologies
Our Products
Download brochure :
"Innovating
Technologies: Meeting the Prion Challenge"
|
